SynAct Pharma
15.35
SEK
-4.06 %
Less than 1K followers
SYNACT
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
-4.06%
-1.03%
+71.22%
+41.85%
+83.96%
+112.48%
-84.47%
+94.52%
+233%
SynAct Pharma operates in the pharmaceutical industry and focuses on the development of innovative treatments for inflammatory diseases. The company researches new therapies that can reduce inflammation and improve patient outcomes. The business is global with a primary presence in Europe and North America. SynAct Pharma was founded in 2016 and is headquartered in Lund, Sweden.
Read moreMarket cap
752.29M SEK
Turnover
2.68M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
27.5
2025
Interim report Q1'25
27.5
2025
General meeting '25
20.8
2025
Interim report Q2'25
ShowingAll content types
Pivotal US Patent Protecting Resomelagon (AP1189) Granted to SynAct Pharma
SynAct’s Nomination Committee proposes Jeppe Ragnar Andersen to the Board
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools